Clinical Trial Update: Safety and Imaging Study of GC1008 in Glioma [Phase 2]

View source ↗

Summary

Phase 2 safety and imaging study of GC1008 (fresolimumab) in glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• GC1008 (fresolimumab)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Primary Brain Tumors | Phase 2 | Status: COMPLETED